BMS sues over generic of blockbuster leukaemia treatment

04-10-2021

Muireann Bolger

BMS sues over generic of blockbuster leukaemia treatment

nitpicker / Shutterstock.com

Bristol-Myers Squibb (BMS) has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel (dasatinib), infringes a pair of patents.


BMS, leukaemia, BMS, Alembic, USPTO, Dr. Reddy’s, Lupin

LSIPR